A Hidden Metastasis with a Bloomy Rind Sign: Carcinomatous Meningitis from Metastatic Lung Adenocarcinoma with Unusual Cranial Nerve Involvement

Abstract

Carcinomatous meningitis, also known as leptomeningeal metastasis, is a rare and often under-recognized manifestation of advanced cancer. It occurs when malignant cells invade the leptomeningeal layers surrounding the brain and spinal cord, leading to a range of neurological symptoms. It remains a diagnostic challenge due to its nonspecific clinical presentation and the complexity of distinguishing it from other neurological conditions. Our case report highlights a rare and unique presentation of carcinomatous meningitis in a patient with an underlying, previously undiagnosed malignancy. The patient initially presented with left-sided facial pain, decreased sensation over the left side of the face, drooling of saliva, and coughing while eating, which raised suspicion for possible posterior fossa lesion. Magnetic resonance imaging (MRI) of the brain with contrast revealed fusiform thickening of the left trigeminal nerve, which was suggestive of a granulomatous lesion. FLAIR also showed bloomy Rind sign. CSF studies showed atypical malignant cells. A multidisciplinary team was set up and endoscopic transnasal transsphenoidal biopsy was done, which was reported as metastatic adenocarcinoma from a primary lung lesion which was confirmed later by PET CT scan. This case emphasizes the importance of considering leptomeningeal metastasis in patients with unexplained neurological signs and symptoms. Multidisciplinary collaboration, including neurosurgery, oncology, and radiology, is essential for accurate diagnosis, staging, and treatment planning. While the prognosis remains poor, early intervention can potentially improve quality of life and extend survival in selected cases.

Keywords

bloomy Rind sign - carcinomatous meningitis - lung adenocarcinoma - malignancy

Publikationsverlauf

Artikel online veröffentlicht:
22. Juli 2025

• References

• 1 Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998; 37 (03) 271-284
• 2 Waki F, Ando M, Takashima A. et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009; 93 (02) 205-212
• 3 Gonzalez-Vitale JC, Garcia-Bunuei R. Meningeal carcinomatosis. Cancer 1976; 37: 2906-2911
• 4 Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagué J. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 2017; 168 (06) 1101-1113.e13
• 5 Olson ME, Chernik NL, Posner JB, York N. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974; 30 (02) 122-137
• 6 Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38 (01) 51-57
• 7 Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 2018; 124 (01) 21-35
• 8 Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology 2010; 74 (18) 1449-1454
• 9 Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49 (04) 759-772
• 10 Mitsuya K, Nakasu Y, Deguchi S. et al. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review. Cancer Imaging 2020; 20 (01) 84
• 11 Liu X, Tan C, Zhu Y. et al. Teaching NeuroImage: bloomy Rind sign of leptomeningeal carcinomatosis. Neurology 2023; 101 (01) e99-e100
• 12 Clarke JL. Leptomeningeal Metastasis From Systemic Cancer [Internet]. Accessed June 25, 2025 at: www.aan.com/continuum